相关实验视频

Updated: May 5, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

简要报告:从EGFR突变的小细胞转变的综合临床基因组分析NSCLC告知了潜在的治疗点

Bingnan Zhang¹, Whitney Lewis², C Allison Stewart¹

¹Department of Thoracic Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

JTO clinical and research reports

|February 15, 2024

概括

EGFR突变非小细胞肺癌 (NSCLC) 转变为小细胞肺癌 (SCLC) 表明预后不佳. 基因组分析确定了转变的SCLC中的新出现的变化和潜在的治疗点,如DLL3,CD276和PTK7.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
翻译研究是翻译研究.

背景情况:

非小细胞肺癌 (NSCLC) 转化为小细胞肺癌 (SCLC) 是已知的抵抗机制,特别是在EGFR突变NSCLC中.
这种转变预示着预后不好,缺乏有效的治疗方法,TP53和RB1功能丧失的风险增加.
对这一患者群体的详细临床基因组特征和治疗目标仍未得到充分研究.

研究的目的:

研究EGFR突变NSCLC转化为SCLC的临床基因组特征.
为了确定新出现的基因组变化和潜在的治疗目标在这个变化的人口.
评估SCLC转化对EGFR突变NSCLC的预后影响.

主要方法:

对34名患有EGFR突变NSCLC转化为SCLC的患者进行了回顾性分析.
从电子医疗记录中提取人口统计,治疗和分子测试数据.
卡普兰-梅尔生存分析,下一代组织/血测序 (NGS) 和患者衍生异种移植的单细胞RNA测序 (scRNA-seq).

主要成果:

从初始诊断到转化后的平均总生存时间为38.3个月和12.4个月.
在转化后继续使用EGFR氨酸激酶抑制剂并没有改善存活率.
在转化后,PIK3CA的改变显著增加 (p=0.04);TP53,RB1和PIK3CA的VAF在纵向上升.
scRNA-seq确定DLL3,CD276 (B7-H3) 和PTK7作为潜在的治疗点.

结论:

在EGFR突变NSCLC中SCLC的转化与预后不佳有关.
临床基因组分析揭示了新出现的变化 (例如,PIK3CA) 并确定了潜在的治疗标 (DLL3,CD276,PTK7).
对这种患者小组,需要进一步验证生物标志物和治疗标.

关键词:

细胞表面的目标是细胞表面.历史学转换的转变在NSCLCLC中,我们可以看到NSCLCLC.奥西默蒂尼布 (Osimertinib) 是一种药物.阻力机制阻力机制在SCLC中,SCLC是最重要的.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...